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Abstract
Background: Limited data describe the prognosis after stereotactic ablative radiotherapy for lung metastases
arising from colorectal cancer. Thus, we evaluated treatment outcomes of stereotactic ablative radiotherapy for
those patients.
Methods: The study involved patients received stereotactic ablative radiotherapy for one to three lung metastases
arising from colorectal cancer at a single institution. A total dose of 40–60 Gy (median, 48 Gy) in three or four
fractions was prescribed.
Results: A total of 79 metastatic lung lesions from 50 patients who underwent curative resection for their primary
colorectal cancer or salvage treatment at a recurrent site were included. The one- and three-year local control rates
were 88.7 % and 70.6 %, respectively. The three-year overall survival and progression-free survival rates were 64.0 %
and 24.0 %, respectively. Patients with tumor volume ≤1.5 mL had a significantly better overall survival rate than
those with tumor volume >1.5 mL (68.0 % vs. 60.0 % at three-year, p = 0.02). Local control was associated with a
trend towards better survival (p = 0.06). No pulmonary complications greater than grade 2 were observed.
Conclusion: Stereotactic ablative radiotherapy is a competitive treatment modality for the management of lung
metastases arising from colorectal cancer.
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Background
The lung is one of the most likely sites of metastases in
the majority of solid-organ cancers [1]. In colorectal
cancer (CRC), the frequency of lung metastases is sec-
ond only to that in the liver [2, 3]. The incidence of lung
metastases associated with CRC is typically reported to
be 8–10 % over the life of the affected patient [2–4]. As
for oligometastases to the liver, lung metastases in CRC
are considered to have been eradicated if the metastatic
tumor burden is relatively low (usually 1 to 3). This con-
sensus was derived from encouraging treatment results
following salvage resection of lung metastases over the
past several decades. Pulmonary metastasectomy, a pro-
cedure introduced by Weinlechnerin in 1882, has been
shown to improve survival in these patients [5]. The 5-
year overall survival (OS) rates of patients undergoing
resection of pulmonary metastases arising from CRC are
in the range of 24–62.7 % for R0 resections and 0–21 %
for R1 resections [6–8]. However, only about 10 % of all
patients with clinically isolated metastases to the lung
from a primary CRC are candidates for pulmonary
metastasectomy because of their medical condition or
refusal to undergo surgery [9]. Patients with untreated
metastatic disease have a 5-year survival rate of less than
5 %, with a median survival time of 10 months [10, 11].
Stereotactic ablative radiotherapy (SABR) is a good
option for patients with pulmonary oligometastases who
are medically inoperable or refuse to undergo surgery.
The use of SABR has increased recently due to the
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recognition that it is a safe and effective treatment for
patients with fewer than four lung metastases [1, 12–14].
Rusthoven et al. reported that actuarial local control (LC)
rates one and two years after SABR of 48–60 Gy for
pulmonary oligometastases were 100 % and 96 %, respect-
ively, with local progression in only one patient [14].
To date, only one study has focused on the feasibility of
SABR for isolated colorectal lung metastases. Kim et al.
investigated the effectiveness of SABR for the treatment of
18 lesions in 13 patients, and reported three-year OS, LC,
and progression-free survival (PFS) rates of 64.7 %, 52.7 %,
and 11.5 %, respectively [15]. Unfortunately however, this
study included too few patients to permit effective com-
parisons of the reported survival outcomes with a surgical
series. In our current study, we report the efficacy of
SABR for lung metastases arising in patients with con-
trolled primary CRC, with homogeneous data generated
from a single radiation oncology unit. Our evaluation of
treatment outcomes included not only LC, but also the
OS and PFS rates.
Materials and methods
SABR for lung metastases
Our institution has developed guidelines for the indica-
tions of SABR for lung metastases arising from lung or
other primary-organ cancers. All patients who were
included in our current retrospective study were treated
in accordance with these strict guidelines at a single insti-
tution between January 2003 and January 2011. We per-
formed SABR for the treatment of lung metastases from
CRC only if a patient satisfied all of the following criteria:
(1) no evidence of recurrence at the primary site; (2) no
extrapulmonary metastasis or other primary cancer; (3)
no mediastinal node metastasis judged by computed tom-
ography (CT) and positron emission tomography/com-
puted tomography (PET/CT); (4) a tumor size smaller
than 5 cm at its longest diameter, with fewer than four
metastatic nodules; (5) no prior thoracic irradiation; (6) an
Eastern Cooperative Oncology Group (ECOG) perform-
ance status of 0–2; (7) no active systemic, pulmonary, or
pericardial infection; (8) adequate hematologic function
(an absolute neutrophil count of >1,500 cells/mm3, and a
platelet count of >100,000 cells/mm3); and (9) refusal of
invasive surgery, unfit for limited resection, or medical
problem(s) including old age or underlying chronic dis-
ease. This study was approved by the Institutional Review
Board of Asan Medical Center, and informed consent was
waived due to the retrospective nature of this study.
SABR technique
Each patient was immobilized in the supine position,
with arms above the head with a vacuum pillow using a
stereotactic body frame (Elekta, Stockholm, Sweden).
Simulation was done using radiation oncology–dedicated
CT (GE LightSpeed RT 16; Healthcare, Waukesha, WI)
with shallow free breathing using a 4D-respiratory gating
system (RPM™, Varian Medical Systems, Palo Alto, CA).
When the treatment site was in the posterior region, the
prone position was selected. All CT images were ob-
tained using a 2.5-mm slice thickness. The gross tumor
volume (GTV) delineated the visible gross tumor at lung
window setting on the end expiratory phase CT image
and the internal tumor volume (ITV) was expanded by
respiratory movement. The planning target volume (PTV)
margin was 5 mm from the ITV. All treatments were
planned and administered using four to eight coplanar
and/or non-coplanar beams generated by a linear ac-
celerator with energies of 6 to 15 MV. A total dose
of 40–60 Gy in three or four fractions to the isodose
line covering the PTV (generally the 85–90 % of the
isodose line) was prescribed according to the physician’s
judgment with consideration of the patient’s general con-
dition, PTV, and radiation dose delivered to normal or-
gans. Contouring and treatment planning were developed
using a 3D radiotherapy planning system (Eclipse V8.0;
Varian Medical Systems, Palo Alto, CA).
Prior to July 2006, all patients were reviewed offline with
CT simulation every other day. Thereafter, cone-beam CT
was performed for image guidance for every treatment
and radiation was administered using LINAC (CL21iX;
Varian Medical Systems, Palo Alto, CA) equipped with an
On-Board Imager (Varian Medical Systems).
Follow-up evaluation after SABR
During SABR, a physician evaluated each patient every
day. After SABR, patients had follow-up examinations
every 1–3 months consisting of physical examination,
blood tests (complete blood count, chemistry, and carci-
noembryonic antigen (CEA) level), chest CT, abdomen
CT, and/or PET/CT. The initial tumor response was
assessed using Response Evaluation and Criteria for
Solid Tumors (RECIST version 1.1) four weeks after
SABR. Local progression was defined as new or progres-
sive lesions arising in the radiation field. Lesions within
radiation pneumonitis or fibrosis that did not change in
size were regarded as an indication of stable disease. Le-
sions arising outside the radiation field within the lung
were defined as out-of-field lung progression. Distant
progression was defined as recurrent disease at any site
outside the lung. Intrathoracic lymph node metastasis
was also regarded as a distant progression. Acute toxic-
ities (radiation pneumonitis, esophagitis, skin reaction,
rib fracture, and hematologic toxicity) were defined as
toxicities that occurred within six months of the com-
pletion of SABR and were graded according to the
Common Terminology Criteria for Adverse Events
(CTCAE; version 4.0).
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Statistical analysis
LC and survival rates were calculated from the last day
of SABR. The probability of cumulative LC and survival
was determined using the Kaplan-Meier method. Group
comparisons were analyzed by the log-rank test. These
analyses were performed using SPSS (version 12.0; SPSS
Inc., Chicago, IL, USA).
Results
A total of 79 metastatic lung lesions from 50 patients
who had undergone curative resection for their primary
CRC or salvage treatment at a recurrent site were treated
with SABR. Twenty-seven of these patients had a solitary
lesion, 17 had two lesions, and six had three lesions. The
median age was 65 years (range, 30–82 years), and 40
(80.0 %) patients had an ECOG PS score of 0–1. Of the 50
patients in the study cohort, 39 (78.0 %) were treated
using SABR for metachronous lung metastases and 11
(22.0 %) for synchronous lung metastases. Thirty two
(64.0 %) cases were inoperable because of old age or med-
ical problems, and 18 (36.0 %) refused surgical treatment.
Eighteen (36.0 %) patients, including 11 with synchronous
lung metastases, did not receive prior chemotherapy be-
fore SABR. Patient and tumor characteristics are summa-
rized in Table 1.
Tumor & SABR characteristics
The median GTV of the 79 lesions was 1.5 mL (range,
0.2–34.8 mL). We prescribed 48 Gy in 4 fractions for 55
lesions, 60 Gy in 4 fractions for 20 lesions, 60 Gy in 3
fractions for 3 lesions, and 40 Gy in 4 fractions for 1
lesion (Table 1).
Tumor response and local control
The median follow-up period was 42.8 months (range,
11.0–104.1 months). The complete response, partial re-
sponse, and stable disease rates were 3.8 %, 26.6 %, and
69.6 %, respectively. The one- and three-year LC rates
were 88.7 % and 70.6 %, respectively (Fig. 1a).
Survival outcomes
The three-year actuarial OS and PFS rates were 64.0 % and
24.0 %, respectively (Fig. 1b). The three-year out-of-field
lung progression-free survival and distant progression-
free survival rates were 39.4 % and 47.9 %, respectively
(Fig. 1c).
Patterns of failure
Local progression as the first site of progression oc-
curred in five patients, out-of-field lung progression in
20 patients, and distant progression in 12 patients. Local,
out-of-field lung, and distant progression occurred in
one patient. Among these, 22 patients received further
chemotherapy.
Toxicities
Only two (4 %) patients experienced grade 2 pulmonary
toxicity (pneumonitis), and there were no grade 3 or
greater complications in our patient cohort.
Factors affecting the treatment outcomes
The results of univariate analyses indicated that the pre-
SABR level of CEA (within normal range; p < 0.01), GTV
(less than 1.5 mL; p = 0.01), and timing of SABR (for a
second or third pulmonary metastasis; p = 0.04) were
statistically significant prognostic factors for LC (Table 2,
Fig. 2a). A SABR dose of 60 Gy showed a trend towards
better LC (p = 0.14) (Table 2, Fig. 2b). Local progression
was observed in only three of 23 cases who received a
dose of 60 Gy.
OS was significantly better according to GTV. Patients
with tumor volume ≤1.5 mL had a better OS rate than
those with tumor volume >1.5 mL (Table 2). Local control
Table 1 Patient and tumor characteristics










1st recurrence 22 (44.0)
2nd recurrence 14 (28.0)
3rd recurrence 3 (6.0)










40 Gy / 4 fx 1 (1.3)
48 Gy / 4 fx 55 (69.6)
60 Gy / 4 fx 20 (25.3)
60 Gy / 3 fx 3 (3.8)
ECOG Eastern Cooperative Oncology Group, SABR stereotactic ablative body
radiotherapy, GTV gross tumor volume, fx fraction
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Fig. 1 a Local control. b Overall survival and progression-free survival. c Out-of-field lung progression-free survival and distant
progression-free survival
Table 2 Univariate analysis of prognostic factors associated with the local control and overall survival
Factors n 3-year LC (%) p value n 3-year OS (%) p value
Age (years) 0.44 0.80
<65 35 73.3 24 58.3
≥65 44 67.5 26 69.2
ECOG performance score 0.43 0.47
0–1 66 71.6 40 70.0
2 12 62.3 9 33.3
Stage of the primary tumor 0.98 0.43
Stage 1–2 20 69.4 13 61.5
Stage 3–4 57 70.9 35 65.7
Timing of SABR 0.04 0.42
First pulmonary metastasis 51 62.6 33 72.7
Second or third 28 90.9 17 47.1
Pre-SABR CEA level <0.01 0.40
≤6 62 78.1 39 64.1
>6 10 0 6 66.7
GTV 0.01 0.02
≤1.5 mL 41 88.5 25 68.0
>1.5 mL 38 50.1 25 60.0
Radiation dose 0.14 0.12
≤48 Gy 56 64.6 33 54.5
60 Gy 23 84.0 17 82.4
LC - 0.06
Yes - - 39 66.7
No - - 11 54.5
LC local control, OS overall survival, ECOG Eastern Cooperative Oncology Group, SABR stereotactic ablative body radiotherapy, CEA carcinoembryonic antigen,
GTV gross tumor volume
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was associated with a trend towards better survival
(Table 2, Fig. 3).
Discussion
SABR is one of several effective treatment options for pa-
tients with pulmonary oligometastases that are medically
inoperable or who refuse to undergo surgery. Several stud-
ies have concluded that SABR is a safe and effective treat-
ment for patients with oligo-lung metastases [1, 12–14].
Rusthoven et al. performed a multi-institutional phase I, II
trial of SABR for pulmonary oligometastases from a var-
iety of primary sites [14]. The study cohort included nine
patients with CRC, and the authors reported actuarial LC
rates of 100 % and 96 % at one- and two years after SABR
with 48–60 Gy, respectively, and a two-year OS rate of
39 %. Local progression occurred in only one patient with
a high-grade extremity sarcoma and no cases of grade 4 or
5 toxicity were observed. Norihisa et al. evaluated their
experience with SABR of 48 Gy or 60 Gy (12 Gy per frac-
tion) in the treatment of oligometastatic lung tumors from
several origins in a total of 34 patients, including nine
cases of CRC. This study reported OS, local relapse-free,
and progression-free rates at two years of 84.3 %, 90.0 %,
and 34.8 %, respectively [13]. Recently, Filippi et al. stud-
ied to estimate SABR efficacy and its potential role as an
alternative to surgery for the treatment of lung metastases
from CRC [16]. Forty consecutive patients who received
SABR as first local therapy were analyzed, two-year OS
rate was 73 % and failure at SABR site was observed in 3
patients (7.5 %).
In our present study, the three-year actuarial LC rate
was 70.6 %. In addition, the three-year LC rate of 82.4 %
for patients receiving 60 Gy was comparable with that
reported in previous studies [1, 12–17]. Subgroup ana-
lysis revealed that a GTV smaller than 1.5 mL indicated
better local control than a GTV larger than 1.5 mL. The
CEA level prior to SABR was another prognostic factor
for LC. We assume that the tumors with an elevated
CEA level are more aggressive in nature and that tumor
control is more difficult than for tumors with a CEA
level in the normal range when using the same prescrip-
tion dose. Furthermore, although LC between 60 Gy and
below 48 Gy was not statistically significant (p = 0.14),
the higher dose may be appropriate to control CRC me-
tastasis to the lungs (Table 2, Fig. 2b). However, because
the present study is limited in terms of events of local
progression, further study is required to define a higher
dose effect for local control.
Fig. 2 Local control according to a GTV and b prescribed dose
Fig. 3 Overall survival according to local control
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A major pattern of failure was found to result from
out-of-field lung progression in our current patient co-
hort. Out-of-field lung progression arose at a rate of
60.6 %, and distant progressions at a frequency of 52.1 %
at three years after SABR (Fig. 1c). Among 38 patients
who experienced recurrence, 20 had out-of-field lung
progressions as the first site of progression. Oligometas-
tases were reported for 11 of these 20 patients, and
multiple metastases for another nine patients. Among
the 11 patients with oligometastases in our study cohort,
ten (50 % of the total patients with out-of-field lung pro-
gression as the first site of progression) received salvage
local treatment, which involved wedge resection and/or
SABR. Half of these patients are currently alive with
stable disease (Table 3).
The three- and five-year actuarial OS rates were 64.0 %
and 35.9 %, respectively. Although the follow-up period
was not long enough and the patient and tumor character-
istics were quite different between surgical series and this
study, making direct comparison challenging, the OS in
this study could be competitive with previous surgical
series that showed a 5-year OS for patients undergoing re-
section of pulmonary metastases in the range of 24–
62.7 % for R0 resections and 0–21 % for R1 resections.
Pfannschmidt et al., in their systematic review of surgical
resection of pulmonary metastases from CRC, demon-
strated that CEA level before treatment was the most
consistently reported potential prognostic indicator for
OS [6]. In studies of surgery, approximately 40–47 % of
the study cohorts had higher CEA levels than normal
[7, 8, 18–20]. However, the results of our present study
included too few patients with high CEA levels (6 patients,
13.9 %) to demonstrate a statistically significant difference
in OS rates. Kim et al. have demonstrated LC and OS
rates of patients with inclusion criteria for SABR that were
similar to the patients in our present study [15]. In their
study, 13 patients (18 lesions) received SABR with doses
in the range of 39–51 Gy in three fractions and showed a
3-year LC rate of 52.7 % and an OS rate of 64.7 %. The
total ITV tended to be associated with OS. In our present
study, GTV was found to be a statistically significant prog-
nostic factor for LC and OS. In addition, the effect of LC
on OS was found to be marginally significant (p = 0.06).
This study has some inherent limitations due to its
retrospective design, including selection bias, numerous
treatment modalities and a short follow-up period. Never-
theless, we utilized a relatively large and homogeneous
study cohort of patients with controlled primary CRC
who received SABR for lung metastases. We observed
promising local control and comparable survival to that of
other local treatment modalities. Further large-scale stud-
ies are needed to compare treatment modalities and define
indications for nonsurgical local treatment modalities for
lung metastasis from CRC.
In summary, we investigated treatment outcomes of
SABR for 79 metastatic lung lesions from 50 patients
who underwent curative resection for their primary CRC
or salvage treatment at a recurrent site. The one- and
three-year LC rates were 88.7 % and 70.6 %, respectively.
The three-year OS and PFS rates were 64.0 % and
24.0 %, respectively. SABR is a feasible, safe, and effect-
ive treatment modality and it should be considered a
competitive treatment modality for the management of
lung metastasis arising from CRC.
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Table 3 Salvage treatment for patients with an out-of-field lung
progression as the first site of progression
Treatment modality
(total 20 patients)
n (%) Final disease status
Stable disease Progressive disease
SABR 8 (40) 3 5
Wedge Resection 2 (10) 2 0
Chemotherapy only 8 (40) 3 5
No further treatment 2 (10) 0 2
SABR stereotactic ablative body radiotherapy
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